A pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, the prodrug comprising a covalently bound VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions, wherein the ocular conditions are diseases characterized by ocular neovascularization, wherein the treatment comprises intraocular administration of the prodrug, wherein the VEGF neutralizing prodrug is a carrier-linked prodrug, wherein one carrier moiety is connected to more than one reversible prodrug linker moiety, either directly or via an optional spacer moiety and wherein each of the reversible prodrug linker moiety is connected to one VEGF neutralizing biologically active moiety, the carrier moiety is a hydrogel moiety and the VEGF neutralizing prodrug comprises a moiety of formula (F-i): wherein D is ranibizumab; the dashed line indicates attachment to the carrier or to the spacer moiety; X 1 is C; or S; X 2 is C(R 7, R 7a); or C(R 7, R 7a)-C(R 8, R 8a); R 1, R 1a, R 2, R 2a, R 3, R 3a, R 7, R 7a, R 8, R 8a are independently selected from the group consisting of H; and C 1-4 alkyl; optionally, the pair R 7a /R 8a forms a chemical bond; optionally, one or more of the pair(s) R 1 /R 1a, R 2 /R 2a, R 7 /R 7a, R 8 /R 8a are joined together with the atom to which they are attached to form a C 3-7 cycloalkyl; or 4- to 7-membered heterocyclyl; optionally, the pair R 7 /R 8 is joined together with the atoms to which they are attached to form a ring A; optionally, R 3 /R 3a are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle; A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; and optionally, the moiety of formula (F-i) is substituted, provided that the hydrogen marked with the asterisk in formula (F-i) is not replaced by a substituent and that R 3 and R 3a are independently of each other H or are connected to N through a sp 3 -hybridized carbon atom. D is ranibizumab; the dashed line indicates attachment to the carrier or to the spacer moiety; X 1 is C; or S; X 2 is C(R 7, R 7a); or C(R 7, R 7a)-C(R 8, R 8a); R 1, R 1a, R 2, R 2a, R 3, R 3a, R 7, R 7a, R 8, R 8a are independently selected from the group consisting of H; and C 1-4 alkyl; optionally, the pair R 7a /R 8a forms a chemical bond; optionally, one or more of the pair(s) R 1 /R 1a, R 2 /R 2a, R 7 /R 7a, R 8 /R 8a are joined together with the atom to which they are attached to form a C 3-7 cycloalkyl; or 4- to 7-membered heterocyclyl; optionally, the pair R 7 /R 8 is joined together with the atoms to which they are attached to form a ring A; optionally, R 3 /R 3a are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle; A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; and optionally, the moiety of formula (F-i) is substituted, provided that the hydrogen marked with the asterisk in formula (F-i) is not replaced by a substituent and that R 3 and R 3a are independently of each other H or are connected to N through a sp 3 -hybridized carbon atom.